TargeGen Overview
- Year Founded
-
2002
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$201M
TargeGen General Information
Description
Developer of small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis), and inflammation. The company offers its products for the treatment of human diseases, such as heart attack, cancer, and eye diseases; vascular leakage, edema, and the unwanted growth of new blood vessels; pleural effusions, arthritis, pulmonary edema, transplant ischemia, ARDS, brain inflammation, hypovolemia (acute blood loss) CNS disorders, and other serious medical conditions.
Contact Information
Website
www.targegen.comCorporate Office
- 9380 Judicial Drive
- San Diego, CA 92121
- United States
Corporate Office
- 9380 Judicial Drive
- San Diego, CA 92121
- United States
TargeGen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 21-Jul-2010 | $201M | Completed | Clinical Trials - Phase 1 | ||
| 4. Later Stage VC (Series D) | 12-Jul-2007 | Completed | Clinical Trials - Phase 1 | |||
| 3. Later Stage VC (Series C) | 31-Aug-2005 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 13-Jan-2004 | $30.6M | $40.6M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 03-Apr-2002 | $10M | $10M | Completed | Product Development |
TargeGen Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | 27,061,947 | $0.000100 | $0.09 | $1.13 | $1.13 | 1x | $1.13 | 22.55% |
| Series A | 10,000,000 | $0.000100 | $0.08 | $1 | $1 | 1x | $1 | 8.33% |
TargeGen Former Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BB Biotech Ventures | Venture Capital | Minority | ||
| CDIB Capital Group | Asset Manager | Minority | ||
| CTI Life Sciences Fund | Venture Capital | Minority | ||
| Chicago Growth Partners | PE/Buyout | Minority | ||
| Enterprise Partners Venture Capital | Venture Capital | Minority |
TargeGen FAQs
-
When was TargeGen founded?
TargeGen was founded in 2002.
-
Where is TargeGen headquartered?
TargeGen is headquartered in San Diego, CA.
-
What industry is TargeGen in?
TargeGen’s primary industry is Pharmaceuticals.
-
Is TargeGen a private or public company?
TargeGen is a Private company.
-
What is the current valuation of TargeGen?
The current valuation of TargeGen is .
-
What is TargeGen’s current revenue?
The current revenue for TargeGen is .
-
How much funding has TargeGen raised over time?
TargeGen has raised $111M.
-
Who are TargeGen’s investors?
BB Biotech Ventures, CDIB Capital Group, CTI Life Sciences Fund, Chicago Growth Partners, and Enterprise Partners Venture Capital are 5 of 12 investors who have invested in TargeGen.
-
When was TargeGen acquired?
TargeGen was acquired on 21-Jul-2010.
-
Who acquired TargeGen?
TargeGen was acquired by Sanofi.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process